8-K: Tenax Therapeutics Secures Key Patent for Levosimendan in PH-HFpEF Treatment

Tenax Therapeutics has received a Notice of Allowance from the USPTO for a patent that significantly broadens intellectual property protection for levosimendan in treating Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF).

Summary

• Tenax Therapeutics has been granted a Notice of Allowance by the United States Patent and Trademark Office (USPTO) for a patent covering the use of levosimendan in treating PH-HFpEF.
• The patent includes claims for oral (TNX-103), subcutaneous (TNX-102), and intravenous (TNX-101) formulations of levosimendan, as well as its active metabolites (OR1896 and OR1855).
• The patent also covers the use of levosimendan in combination with various cardiovascular drugs for PH-HFpEF treatment.
• This new patent will provide intellectual property protection until December 2040, with potential for extension.
• The company has initiated Phase 3 trials for levosimendan (LEVEL study) with 152 subjects randomized to receive either levosimendan or a placebo.
• The primary outcome measure for the Phase 3 study is the six-minute walk distance from baseline to week 12.
• The company's Phase 2 HELP trial showed that IV levosimendan improved the 6-minute walk distance by 29 meters compared to placebo (p=0.03).

Sentiment

Score: 8

Explanation: The document is very positive due to the patent allowance, the positive Phase 2 trial results, and the initiation of a Phase 3 trial. However, there are risks related to funding and regulatory approval.

Positives

• The patent significantly broadens Tenax's IP protection for levosimendan in PH-HFpEF.
• The patent covers multiple routes of administration (oral, subcutaneous, IV) and combinations with other cardiovascular drugs.
• The patent provides IP protection until December 2040, with potential for extension.
• The company has initiated a Phase 3 trial for levosimendan.
• The Phase 2 HELP trial demonstrated a statistically significant improvement in exercise capacity with levosimendan.

Risks

• The company's future success depends on the outcome of clinical trials, including the Phase 3 LEVEL study.
• There are risks related to regulatory review and approval of product candidates.
• The company relies on third parties, including Orion Corporation, for manufacturing and clinical research.
• There are risks related to the formulation, production, marketing, customer acceptance and clinical utility of product candidates.
• The company's ability to raise additional capital to fund operations is a risk.
• The company faces risks related to its continued listing on Nasdaq.

Future Outlook

Tenax Therapeutics is focused on advancing the development of levosimendan for PH-HFpEF, including the ongoing Phase 3 LEVEL study. The company is also exploring the potential of levosimendan in other related areas of cardiovascular disease. The company is also developing a unique oral formulation of imatinib.

Management Comments

• Chris Giordano, President & Chief Executive Officer of Tenax Therapeutics, stated that the patent significantly broadens their existing IP claims and provides additional rationale for the future development of various drug-drug combinations with levosimendan.
• Dr. Stuart Rich, Chief Medical Officer of Tenax Therapeutics, noted the high prevalence and poor outcomes of PH-HFpEF and highlighted levosimendan's unique mechanism of action.

Industry Context

The announcement is significant as there are currently no approved drugs for PH-HFpEF, a condition with high morbidity and mortality. Tenax's levosimendan is a potential novel treatment option, and the patent strengthens its position in this space. The company is competing with other pharmaceutical companies that are also developing treatments for heart failure and pulmonary hypertension.

Comparison to Industry Standards

• The 29-meter improvement in the 6-minute walk test in the HELP study is a positive result compared to other treatments for heart failure, where improvements are often smaller.
• The lack of approved treatments for PH-HFpEF makes levosimendan a potential first-in-class therapy if approved.
• Other companies such as Bayer and Merck are also developing treatments for heart failure, but none have specifically targeted PH-HFpEF with the same mechanism of action as levosimendan.

Stakeholder Impact

• Shareholders will likely view the patent allowance and positive clinical trial results favorably.
• Patients with PH-HFpEF may benefit from a new treatment option if levosimendan is approved.
• Employees may be positively impacted by the company's progress and potential for growth.

Next Steps

• Tenax will continue the Phase 3 LEVEL study of oral levosimendan in PH-HFpEF patients.
• The company will pursue the granting of the patent by the USPTO.
• Tenax will explore the clinical utility of levosimendan in other related areas of cardiovascular disease.

Key Dates

Keywords

levosimendan, PH-HFpEF, pulmonary hypertension, heart failure, patent, TNX-103, TNX-102, TNX-101, intellectual property, cardiovascular, clinical trial, Phase 3, exercise performance